Paclitaxel impairs adipose stem cell proliferation and differentiation

Rachel L. Choron, Shaohua Chang, Sophia Khan, Miguel A. Villalobos, Ping Zhang, Jeffrey P. Carpenter, Thomas N. Tulenko, Yuan Liu

Research output: Contribution to journalArticle

Abstract

Background Cancer patients with chemotherapy-induced immunosuppression have poor surgical site wound healing. Prior literature supports the use of human adipose-derived stem cell (hASC) lipoinjection to improve wound healing. It has been established that multipotent hASCs facilitate neovascularization, accelerate epithelialization, and quicken wound closure in animal models. Although hASC wound therapy may benefit surgical cancer patients, the chemotherapeutic effects on hASCs are unknown. We hypothesized that paclitaxel, a chemotherapeutic agent, impairs hASC growth, multipotency, and induces apoptosis. Methods hASCs were isolated and harvested from consented, chemotherapy and radiation naive patients. Growth curves, MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide), and EdU (5-ethynyl-2-deoxyguridine) assays measured cytotoxicity and proliferation. Oil Red O stain, Alizarin Red stain, matrigel tube formation assay, and quantitative polymerase chain reaction analyzed hASC differentiation. Annexin V assay measured apoptosis. Immunostaining and Western blot determined tumor necrosis factor α (TNF-α) expression. Results hASCs were selectively more sensitive to paclitaxel (0.01-30 μM) than fibroblasts (P < 0.05). After 12 d, paclitaxel caused hASC growth arrest, whereas control hASCs proliferated (P = 0.006). Paclitaxel caused an 80.6% reduction in new DNA synthesis (P < 0.001). Paclitaxel severely inhibited endothelial differentiation and capillary-like tube formation. Differentiation markers, lipoprotein lipase (adipogenic), alkaline phosphatase (osteogenic), CD31, and van Willebrand factor (endothelial), were significantly decreased (all P < 0.05) confirming paclitaxel impaired differentiation. Paclitaxel was also found to induce apoptosis and TNF-α was upregulated in paclitaxel-treated hASCs (P < 0.001). Conclusions Paclitaxel is more cytotoxic to hASCs than fibroblasts. Paclitaxel inhibits hASC proliferation, differentiation, and induces apoptosis, possibly through the TNF-α pathway. Paclitaxel's severe inhibition of endothelial differentiation indicates neovascularization disruption, possibly causing poor wound healing in cancer patients receiving chemotherapy.

Original languageEnglish (US)
Pages (from-to)404-415
Number of pages12
JournalJournal of Surgical Research
Volume196
Issue number2
DOIs
StatePublished - Jun 15 2015
Externally publishedYes

    Fingerprint

Keywords

  • Cancer therapy
  • Chronic wounds
  • Human adipose-derived stem cells
  • Neovascularization
  • Paclitaxel
  • Wound healing

ASJC Scopus subject areas

  • Surgery

Cite this

Choron, R. L., Chang, S., Khan, S., Villalobos, M. A., Zhang, P., Carpenter, J. P., Tulenko, T. N., & Liu, Y. (2015). Paclitaxel impairs adipose stem cell proliferation and differentiation. Journal of Surgical Research, 196(2), 404-415. https://doi.org/10.1016/j.jss.2015.03.026